DNA
Ginkgo Bioworks Holdings, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +5 | 25.52M | $252.75M | +9 | −4 |
| Q1 2026 | 72 | -1 | 23.15M | $141.95M | +6 | −7 |
| Q4 2025 | 73 | +2 | 24.08M | $200.09M | +2 | — |
| Q3 2025 | 15 | -2 | 16.22M | $236.55M | — | −2 |
| Q2 2025 | 14 | 0 | 15.99M | $179.94M | +2 | −2 |
| Q1 2025 | 11 | -3 | 10.22M | $58.26M | — | −3 |
| Q4 2024 | 14 | +3 | 10.20M | $100.21M | +3 | — |
| Q3 2024 | 10 | -3 | 9.70M | $79.02M | — | −3 |
| Q2 2024 | 13 | — | 419.17M | $140.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 143.09M | — | $47.83M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 134.43M | — | $44.94M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 134.43M | — | $44.94M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 134.43M | — | $44.94M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 134.43M | — | $44.94M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Glenview Capital ✦ | 26.50M | — | $8.86M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | ARK Investment Management ✦ | 23.85M | — | $7.97M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 19.41M | — | $6.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 17.43M | — | $5.80M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 17.43M | — | $5.80M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 15.63M | — | $5.22M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 15.31M | — | $5.12M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 15.31M | — | $5.12M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 10.36M | — | $3.39M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 10.36M | — | $3.39M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 6.37M | — | $2.13M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 3.00M | — | $991,000 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 3.00M | — | $991,000 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 2.18M | — | $728,742 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 1.62M | — | $542,370 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 140 shares, $0 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 330 sh · $2,302
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology